Progenics Pharmaceuticals Competitors and Similar CompaniesClear all
Progenics Pharmaceuticals's competitors and similar companies include Clovis Oncology, Halozyme Therapeutics, Pharmacyclics and Biocon.
 Progenics Pharmaceuticals Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients. |  Clovis Oncology Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  Pharmacyclics Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. | ||
Founding Date | Founding Date 1986 | Founding Date 2009 | Founding Date 1998 | Founding Date 1991 | Founding Date 1978 |
Type | Type Subsidiary | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations New York, US HQ Billerica, US | Locations San Diego, US HQ | Locations Sunnyvale, US HQ | Locations Bengaluru, IN HQ Bengaluru, IN Nanakramguda, IN Dublin, IE Kuala Lumpur, MY Puchong, MY Delémont, CH see more | |
Employees | Employees 49 | Employees 4843% increase | Employees 373157% increase | Employees 6551% decrease | Employees 16,5612% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 10.6 m | Valuation ($) 6.4 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $35m (FY, 2019) | Revenue (est.) $148.8m (FY, 2021) | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) $729.7m (FY, 2014) | Revenue (est.) ₹167.8b (FY, 2026) |
Cost of goods | Cost of goods $3.2m (FY, 2019) | Cost of goods N/A | Cost of goods $228.8m (FY, 2025) | Cost of goods $40.4m (FY, 2014) | Cost of goods ₹56.9b (FY, 2026) |
Gross profit | Gross profit $31.8m (FY, 2019) | Gross profit N/A | Gross profit $1.2b (FY, 2025) | Gross profit $689.3m (FY, 2014) | Gross profit ₹115.8b (FY, 2026) |
Net income | Net income ($68.6m) (FY, 2019) | Net income ($264.5m) (FY, 2021) | Net income $316.9m (FY, 2025) | Net income $86.1m (FY, 2014) | Net income ₹3.7b (FY, 2026) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 357m | Total funding raised $ 171.9m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Clovis Oncology
HQ
Boulder, US
Employees
484↑ 3% increase
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents.
View companyHalozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyPharmacyclics
HQ
Sunnyvale, US
Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases.
View company
Biocon
HQ
Bengaluru, IN
Employees
16,561↑ 2% increase
Biocon is a company that develops and manufactures biopharmaceutical products.
View company